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ABSTRAK 
KESAN RHEUMATOID ARTHRITIS KE ATAS SISTEM 
RESPIRATOR!- FISIOLOGI DAN RADIOGRAF 
Latar Belakang 
Kesan penyakit rheumatoid arthritis ke atas sistem pemafasan boleh dilihat 
dalam beberapa bentuk termasuk kesan ke atas selaput pleura, nodul paru-
paru, interstitial pulmonary fibrosis, and obliterative bronchiolitis. 
Eihnan dalam tahun 194 7 telah menunjukkan terdapatnya kesan pada kedua-
dua lobar paru-paru dalam pesakit rheumatoid arthritis dan lebih banyak kes 
dikesan selepas itu. Selain daripada kesan di atas, penyakit yang lebih teruk 
yang mengakibatkan kerosakan pada fungsi paru-paru boleh terjadi di dalam 
pesakit RA walaupun X-ray dada menunjukkan paru-paru dalam keadaan 
normal. 
Dalam tahun 1994, M. Linstow dan rakan penyelidik telah juga 
menunjukkan pesakit dengan penyakit RA mempunyai fungsi paru-paru 
yang abnormal. 
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Objektif 
Tujuan utama penyelidikan ini adalah untuk mengkaji prevalen dan kesan 
penyakit RA ke atas paru-paru mereka. Kesan ini dikaji dengan 
menggunakan spirometri untuk melihat fungsi paru-paru di dalam pesakit 
RA manakala kajian kesan penyakit ke atas paru-paru dilihat dengan 
menjalankan ujian radiografi. Objektif selanjutnya adalah untuk melihat 
kesan aktiviti penyakit ke atas paru-paru. 
Metodologi 
Penyelidikan telah dijalankan diantara bulan November 2000 hingga 
Oktober 200 1. Pesakit rheumatoid arthritis yang menghadiri Klinik 
Rheumatoid dan dimasukk:an ke dalam wad, Hospital Universiti Sains 
Malaysia yang telah memenuhi kriteria kemasukan dan penyisihan dikenal 
pasti. Semua pesakit mestilah disahkan diagnosis rhewnatoid arthritis 
menggunakan kriteria dari American Rheumatic Association. Apabila telah 
dikenal pasti, penerangan ringkas mengenai penyelidikan diberi. 
Pemeriksaan asas tennasuklah ujian penuh sistem darah termasuk kadar 
sedimentasi sel darah merah, ujian fungsi renal dan hati. Kesan ke atas 
sistem immunologi diselidik dengan mengambil penyiasatan faktor 
rheumatoid, factor anti-nuklear, kadar sistem komplemen dan protein 
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reaktif-C. Penyiasatan spirometri akan dijalankan kepada semua pesakit dan 
bacaan yang tertinggi akan diambil untuk keputusan akhir. Kesemua pesakit 
juga dikehendaki menjalani pemeriksaan radiografi paru-paru dan simptom 
penyakit paru-paru contohnya batuk berpanjangan dan kesesakan nafas 
ditanya. Pesakit juga akan diperiksa kewujudan krepitasi pada bahagian 
bawah paru-paru secara klinikal. 
Keputusan 
Keputusan menunjukkan terdapat perbezaan yang signiftkan di antara purata 
FVC, FEVt dan FEVt/FVC dalam pesakit rheumatoid arthritis 
dibandingkan dengan nilai jangkaan yang diselaraskan mengikut nilai 
normal di dalam populasi. 
Jenis fungsi respiratori yang paling kerap ditemui dalam pesakit rheumatoid 
arthritis ialahjenis restriktif di mana FVC% adalah kurang dari 80%. 
Ujian radiograf paru-paru mengesan 12 ftlem radiograf yang abnormal 
dalam pesakit RA dan daripada jumlah tersebut, 50% mempunyai fungsi 
paru-paru yang normal. Radiograf paru-paru abnormal yang paling kerap 
dijumpai adalah 'peribronchial thickening and/or pleural thickening' dan 
'interstitial lung disease'. 
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84.6% pesakit yang mempunyai radigraf paru-paru yang normal mempunyai 
ujian fungsi paru-paru jenis restriktif. Di dalam kajian ini di dapati tidak ada 
perkaitan di antara tanda-tanda penyakit dan aktiviti penyakit dengan fungsi 
paru-paru. 
Kesimpulan 
Fungsi fisiologi sistem paru-paru ke atas pesakit rhewnatoid arthritis adalah 
abnormal walaupun mereka tidak mempunyai simptom atau tanda-tanda 
penyakit. Kebanyakan pesakit mempunyai kesan restriktif ke atas sistem 
paru-paru mereka. Pengesanan kesan ini adalah lebih baik menggunakan 
spirometri dibandingkan dengan radiografi paru-paru. Fungsi paru-paru ini 
tidak dipengaruhi oleh tanda-tanda penyakit, kesan ke atas radiografi paru-
paru dan aktiviti penyakit rheumatoid arthritis. 
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ABSTRACT 
RESPIRATORY INVOLVEMENT IN RHEUMATOID ARTHRITIS-
PHYSIOLOGIC ABNORMALITIES AND DETERMINANTS OF 
RADIOGRAPIDC 
Background 
Pulmonary disease in rheumatoid arthritis (RA) may take many forms 
including pleural lesions, lung nodules, interstitial pulmonary fibrosis, and 
obliterative bronchiolitis. In 1947, Ellman first described diffuse bilateral 
interstitial changes in the lungs of a patient with rheumatoid arthritis and 
many similar cases have been reported throughout the world. In addition to 
the distinct lung disorders mentioned above, low grade disease of the 
respiratory tract, and even considerable impairment of respiratory function, 
may occur in rheumatoid arthritis in spite of radiologically normal lungs. M. 
Linstow and colleagues in 1994 have showed that patients suffering from 
RA have prominent functional pulmonary abnormality. 
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Objective 
The aim of this study is to evaluate prevalence and characteristic of 
respiratory involvement in patients with rheumatoid arthritis. The 
characteristic will be determined by doing a lung function test in all patient 
confmned to have rheumatoid arthritis while evaluation of the radiographic 
changes is done with a chest radiograph. The second objective is to assess 
the relationship between disease activity and lung involvement. 
Subjects and methods 
The study was carried out during a period between November 2000 to 
October 2001. The patients were recruited from Rheumatology Clinic and 
medical wards, Hospital Universiti Sains Malaysia who fulfllled inclusion 
and exclusion criteria. All patients should satisfy the American Rheumatic 
Association criteria for Rheumatoid Arthritis. Once patients were identified, 
a brief explanation of the study was made. Baseline investigations includes 
full blood count, erythrocyte sedimentation rate, renal and liver function test. 
The immunological system is evaluated by doing a rheumatoid factor, 
complement level and C-reactive protein. Lung function test were 
performed for all patients and highest reading was taken as the fmal result. A 
chest radiograph was done on all patients included in this study. They were 
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also asked for associated respiratory symptoms of chronic cough, shortness 
of breath and assessed of presence of basal crepitations clinically. 
Results 
There were significant different in the mean FVC, FEVt and FEVt/FVC of 
patients with RA as compared to normal population. The most common 
types of respiratory function abnormality in patients with RA was restrictive 
type where the FVC% was less than 80%. 
Assessment of chest radiograph revealed twelve abnormalities in the chest x-
ray of RA patients and out of this , 50% of the lung function test is normal. 
The most common abnormalities detected is peribronchial and/or pleural 
thickening and interstitial lung disease. 
While 84.6% of patients with normal chest x-ray had restrictive type of 
abnormality on their lung function test. There were no relationship between 
the sign and disease activity with lung function test. 
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Conclusion 
The physiological function of the respiratory system in rheumatoid arthritis 
patients are abnormal eventhough they remain asymptomatic. 
The most common abnormalities in rheumatoid lung disease by doing the 
lung function test is the restrictive type. Lung function test predicts lung 
abnormalities better than assessment of chest radiography. The lung function 
is not affected by sign, chest radiographic fmding and activity of disease. 
However there is suggestion that the longer the disease, the more likely to 
have abnormal and more severe impairment of the lung function test. 
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CHAPTER I 
INTRODUCTION 
1.1. Physiologic Abnormalities 
Physiologic abnormalities are common in rheumatoid arthritis (RA). 
Abnormalities suggestive of interstitial lung disease (ILD) are reported in 
22%-40% of patients (Hakala M. 1988, Anaya J-M et al1995). The changes 
most commonly seen in association with ILD parellel those of any fibrosing 
lung disease include reduction in lung volumes, pulmonary compliance and 
abnormalities in diffusing capacity for carbon monoxide (DLCO). Many RA 
patients with normal chest radiographs may be found to have abnormalities 
in pulmonary functions. Physiologic testing also often shows evidence of 
obstruction to airflow, which may reflects other pulmonary manifestation of 
RA including bronchiectasis, bronchiolitis obliterans, chronic airway 
obstruction, or cricoarytenoid arthritis (King TE 1998, Lake FR et al 1996, 
Shannon TM et al 1992) 
The goal of physiology is to explain the physical and chemical factors that 
are responsible for the origin, development, and progression of the disease. 
The diagnosis and treatment of most respiratory disorders have come to 
depend heavily on an understanding of the basic physiological principles of 
respiration and gas exchange (Rhoades and Pflanzer 1996). 
1.1.1. Factors Affecting Physiologic Abnormalities 
Diseases that alter pulmonary function tests can be divided into obstructive 
and restrictive disorders. With an obstructive disorders, expiratory flows are 
obstructed, and with restrictive disorder, lung inflation is restricted. 
Obstructive diseases include bronchial asthma and chronic obstructive 
airway disease (COAD) while restrictive diseases include interstitial lung 
disease in connective tissue diseases, chest wall and pleural derangements 
and neuromuscular diseases. 
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1.1.2. Methods Used to Assess Physiologic Abnormalities 
A simple method for studying pulmonary function is to record the volume 
movement of air in and out of the lungs, a process called spirometry. One of 
the most useful test is to assess the overall ability to move air in and out of 
the lungs (ventilation) is called forced vital capacity (FVC). This is the 
maximum amount of air that can be breath forcefully and rapidly exhaled 
after a deep breath. From FVC, another important determinant that can be 
obtained is the forced expired volume exhaled in one second. This volume is 
termed forced expiratory volume (FEV I) has the least variability of the 
measurements obtained from a forced expiratory manoeuvre and is 
considered one of the most reliable measurement. 
Another useful way of expressmg FEV 1 is as percentage of FVC 
(i.e.FEVt/FVC x 100), which corrects for the differences in lung size. 
Nonnally FEVt is 80% or more of the FVC (i.e, 80% of an individual's 
forced vital capacity can be exhaled in the frrst second) 
In obstructive lung disorders, FVC and FEVt are both reduced with a 
prominent reduction in FEVI and the ratio of FEVt/FVC is reduced 
drastically below normal (<80%). In restrictive type, both FVC and FEV1 
are reduced making the ratio of FEV1/FVC is normal or slightly higher 
(Rhoades and Pflanzer 1996) 
The typical fmdings of RA associated lung disease include reduced lung 
volumes and diminished diffusion capacity and hypoxemia, a fmdings 
characteristic of restrictive lung disease. Kenneth et al in 1996 have found at 
least 32.4% abnormal fmdings was identified by pulmonary function test as 
restrictive type in 336 patients with rheumatoid arthritis and known lung 
disease. These abnormal fmdings include FVC < 80% of predicted in 42 
patients and evidence of radiographic infiltrates in 40 patients (Kenneth et al 
1996). 
Other study done by Perez T et al found 18% of 50 studied patients with RA 
had an obstructive type of lung function abnormality. 
1.2. Radiographic Abnormalities 
Pulmonary disease in rheumatoid arthritis may take many forms, including 
pleural lesions, lung nodules, and interstitial lung disease. Rheumatoid 
arthritis interstitial lung disease (RA-ILD) is particularly debilitating, with 
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reported prevalence ranging from <2% to >40% and a survival rate as low as 
39% (Hakala M 1988 , Anaya J-M et al 1995). The most common 
manifestations are pleural abnormalities and ILD. In ILD, the most common 
fmding is that of bilateral interstitial abnormalities that are asymmetric 
( Remy-Jardin et al 1994, Roschman RA et al 1987). Fibrosing alveolitis 
may be apparent on the chest radiograph in approximately 5% of patient. It 
usually produces basal reticular nodular shadowing, but may progress to a 
coarser and more widespread lung field involvement and honeycombing 
may appear (Locke GB 1963). As fibrosis advances, there is a tendency for 
severe volume loss. Disease progression results in a more reticular nodular 
pattern (David Sutton). 
1.2.1. Methods Used to Determine Radiographic Abnormalities 
Depending on the diagnostic modality used to detect disease, prevalence 
rates of ILD in RA are reported with wide variance. Radiographically, the 
changes seen with ILD and RA are indistinguishable from those seen with 
idiopathic pulmonary fibrosis or ILD associated with other connective tissue 
diseases (Lynn T. Tanoue 1998). 
The plain chest radiograph is an insensitive means of identifying ILD, 
yielding a prevalence rate of 2%-6%. High Resolution CT Scanning (HR.Cn 
is more sensitive method of detecting interstitial changes in fibrosing lung 
disease (Hansell DM et al 1991 ). The prevalence of pulmonary interstitial 
changes in RA identified by HRCT is reported from 10%-47%. 
1.3. Rheumatoid Arthritis 
Rheumatoid arthritis affects about 1% of the population worldwide. The 
natural history of the disease is characterized by the infiltration of 
immunocompetent cells into the synovial fluid and tissue, and stimulation 
and proliferation of synovial fibroblast (Edward D. Harris, JR.1990 ). 
Epidemiologic studies have shown that 30% of patients developed 
pathological joint erosions within the frrst year and 70% within 2 years 
(Joachim R. Kalden 2001, Van der Hiejde DM 1995 ). Based on the 
epidemiologic data, RA can no longer be considered a benign disease that 
only affects joint function, since statistical analyses have shown increased 
mortality compared to general population (Mitchell DM et al 1986, Scott DL 
et all987). 
Rheumatoid arthritis is usually an aggressive disease that needs to be treated 
forcefully if subsequent deformity and disability are to be reduced. The long 
term outcomes in RA include not only joint destruction, work and functional 
disability, psychological dysfunction, and treatment related side effects as 
well as associated co-morbid illnesses. Any of these can potentially 
compromise the quality of life and life expectancy (Peter Brooks, 1998). 
1.3.1. Detination 
Rheumatoid arthritis is a systemic disease characterized by subacute or 
chronic non-suppurative inflammatory arthritis that affects mainly peripheral 
joints, usually in a symmetric manner. It characteristically follows a 
prolonged course of exacerbation and remission (Gary W.Hunninghake, 
Anthony S.Fauci 1979). 
1.3.2. Pathogenesis 
The cause of rheumatoid arthritis is unknown. Indeed, it is possible that 
many different arthritogenic stimuli activate the immune response in the 
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immunogenetically susceptible host. The presentation of a relevant antigen 
to an immunogenetically susceptible host is believed to trigger rheumatoid 
arthritis. 
The pathogenesis of RA will be divided into 5 stages (Edward D.Harris 
1990):-
1. Stage I 
Antigen- presenting cells (APC) such as macrophages of dendritic cells in 
the synovial membrane are the frrst to be involved in the human immune 
response. These APC ingest, process, and present foreign proteins antigens 
to T -lymphocytes, which initiate a cellular immune response and stimulate 
the differentiation of B-lymphocytes into plasma cells that secrete antibody. 
The patient will probably has no symptom during this stage. 
u. Stage 2 
T -lymphocytes and antigen initially activate B-lymphocytes in the synovial 
membrane. The B-cells then proliferate, and some differentiate into 
antibody-secreting cells. These steps are mediated by cytokines, particularly 
interleukin-2. The production of antibodies within an expanding scaffold of 
new blood vessels and synovial-cell proliferation lead to process called 
angiogenesis (Koch AE et al 1986). The development of an extensive 
network of new blood vessels in the synovial membrane is essential to the 
evolution of rheumatoid arthritis. During this stage, the patient will 
complaint of malaise, mild joint stiffness and swelling without abnormality 
detected radiologically. 
111. Stage 3 
Accumulation of neutrophils in the synovial fluid acts as the 
chemoattractants within the joint space. Once within the joint fluid, 
neutrophils probably are rapidly activated by the phagocytosis of cellular 
debris and aggregates of immune complexes. The activation of neutrophils 
results in degranulation, with the release of proteinases (Hibbs MS et al 
1984) and the production of additional chemotactic stimuli, such as 
leukotrienes B4, reactive oxidants and products of arachidonic acid 
metabolism (Ehmgreen J.et al1987). 
There will be a balance of the above effect and prevent the unwanted 
adherence of neutrophils at the non-inflammatory sites. The inhibitor of 
interactions that is Interleukin-8, is produced by endothelial cells and 
fibroblast (Gimbrone MA Jr et al 1989). The synovial cell proliferation 
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occurs without polarization or invasion of cartilage. The patient will present 
with joint pain and swelling, and morning stiffuess. The radiographic 
changes in this stage is soft tissue swelling. 
tv. Stage 4 
The irreversible destruction of cartilage occurs in stage 4 of the disease. It 
begins when proliferating synovial membrane becomes organized in an 
invasive front that invades cartilage, tendons, and subchondral bone and lead 
to destruction. 
The principles proteinases released by rheumatoid synovial cells, 
collagenase and stromelysin, are capable of destroying almost all the matrix 
proteins present in articular cartilage and bone. 
There will be more pronounced swelling of the joints and morning stiffness 
will be present. At this stage, the MRI reveals proliferation pannus with 
radiographic evidence of periarticular osteopaenia. 
v. Stage 5 
By the time rheumatoid arthritis reached stage 5, irreversible destruction of 
cartilage is well underway, and attempts to protect joints from progressive 
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destruction are futile. There will be erosion of subchondral bone, invasion of 
cartilage by pannus, chondrocyte proliferation and stretching of the 
ligaments around the joints. 
The patient will have joint swelling and pain plus loss of function and early 
deformity. Clinically, there will be instability of the joints, flexion 
contractures, decreased range of motion with extra-articular complications. 
The precise pathogenic mechanism whereby lung lesions arise in rheumatoid 
arthritis remains unclear and there is little relevant information on the 
interstitial lung disease of RA. There is some direct evidence for the local 
production of TNF-alpha. Alveolar macrophages isolated from broncho-
alveolar lavage (BAL) of RA patients with and without interstitial lung 
disease produced significantly increased amount of TNF-alpha compared to 
normal controls (Gosset P, Perez T, Lassalle P et al 1991). There was no 
difference noted in IL-l levels. Additionally, alveolar macrophages from 
patients treated with disease-modifying agents (DMARDs) or corticosteroids 
produced significantly less TNF-alpha. 
Fibrosis is usually associated with increased synthesis and turnover of 
collagen. Neutrophils collagenase levels were increased in those RA patients 
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with evidence of interstitial lung disease compared to other RA patients 
(Gilligan DM et al 1990, Weilland JE et al 1987 ). One study demonstrated 
that 11 of the 14 RA patients with established interstitial lung disease had 
increased neutrophils, collagenase, and Type m procollagen peptide levels 
in the lavage fluid (Gilligan DM et all 1990 ). Lavage cells (probably 
macrophages) released increased levels of neutrophils chemotactic activity 
( presumably IL-8) which probably was responsible for the directed 
migration of neutrophils to the inflammatory site (Garcia JG 1987, James 
HL et al1999). 
1.3.3. Diagnosis of Rheumatoid Arthritis 
The frrst criteria for the classification of rheumatoid arthritis were published 
in 1958. These were used heavily for 30 years and were revised in 1988. The 
revised criteria were formulated from a computerized analysis of 262 
contemporary, consecutively studied patient with RA and 262 control 
subjects with rheumatic disease other than RA (Arnett FC, Edworthy SM, 
Bloch DA, et al1988). 
It is important to note that the criteria were designed principally for disease 
classification for epidemiologic purposes, not for diagnosis in individual 
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cases. Most rheumatologist believed that the diagnosis of rheumatoid 
arthritis must be made on clinical grounds in individual patients. 
Nonetheless, the following criteria are useful as guidelines for making the 
diagnosis:-
a. Morning stiffness in and around joints lasting at least one hour before 
maximal improvement is noted. 
b. Swelling of the soft tissue (arthritis) observed by physician around 
three or more joints. At least 3 joint areas have soft tissue swelling or 
joint effusions, not just bony overgrowth. The 14 possible joint areas 
involved are right or left proximal interphalangeal, 
metacarpophalangeal, wrist, elbow, knee, ankle and 
metatarsophalangeal joints. 
c. Swelling (arthritis) of the proximal interphalangeal, 
metacarpophalangeal or wrist joints. 
d. Symmetric arthritis, simultaneous involvement of the same joint areas 
on both side of the body. 
e. Subcutaneous nodule over bony prominences, extensor swfaces, or 
juxtaarticular region observed by a physician. 
f. A positive test for Rheumatoid Factor. 
g. Radiographic evidence of erosions, periarticular osteopenia, or both in 
the joints of the hand, wrist, or both. 
To make a diagnosis of rheumatoid arthritis, at least the frrst four symptoms 
must have been present for six or more weeks. 
For classification purposes, a patient shall be said to have rheumatoid 
arthritis if she/he has satisfied at least 4 out of these 7 criteria above. Patients 
with 2 clinical diagnoses are not excluded. 
These new criteria demonstrate 91 to 94 percent sensitivity and 89 percent 
specificity for the diagnoses of rheumatoid arthritis (Arnett FC et al1988). 
1.3.4. Management of Rheumatoid Arthritis 
The goal of therapy of rheumatoid arthritis are to relief pain, reduction of 
inflammation, protection of articular structures, maintenance of function and 
control of systemic involvement. None of the therapeutic interventions is 
curative, and therefore all must be viewed as palliative, aimed at relieving 
the signs and symptoms of the disease (Fauci et all1998). 
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Management of patients with RA involves an interdisciplinary approach. 
The value of informing patients and their families about the nature of 
rheumatoid arthritis, its tendency to have remission followed by flares of 
activity, its potential effects on the activities of daily living and energy levels 
are very important and should be reinforced constantly (Lorig KR, Lubek D, 
et al1985). 
Adequate rest matched with non-weight bearing exercises to maintain or 
increase muscle tone without exacerbating joint inflammation is also 
important aspect of the therapeutic regimen. The inflamed joint is 
particularly vulnerable to the effects of motion. In joint with effusions, 
exercise may lead to the development of intraarticular pressures sufficient to 
shut down synovial blood flow, resulting in ischaemia and tissue damage 
from oxygen metabolites during reperfusion after the motion-induced 
hypoxia (Merry P, Winyard PG, et al1989). 
Modification in diet may be helpful if the patient can tolerate it. There is 
evidence that substituting omega-3 fatty acids such as eicosapentaenoic acid 
found in certain fish oils or plants for dietary omega-6 essential fatty acids 
found in meat (Pike MC 1989, Harrison's Textbook 1998).0mega-3 fatty 
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acids may decrease the production of leucotriene B4, Interleukin-1 beta, 
Interleukin-1 alpha, and tumor necrosis factor by stimulated peripheral blood 
mononuclear cells (Sperling RI et al 1987, Endress S et al 1989). Clinical 
improvement was noted in groups of patients with rheumatoid arthritis who 
were treated with supplemental icosapentaenoic acid and docosahexanoic 
acid (Kremer JM, Jubiz W, et al1987). 
Medical management of rheumatoid arthritis includes non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids and disease modifying anti 
rheumatic drugs (DMARDs). Historically, DMARDs were viewed as toxic 
drugs and to be introduced if absolutely necessary. The alternative name for 
it was second line therapy, implying that other therapies such as analgesic 
and NSAIDs had to have failed in controlling patient's symptoms before 
DMARDs were justified (Emery P, Conaghan P, Quinn M 2001 ). Now early 
used of anti rheumatic drugs reduces long term disability in RA. Early 
treatment of rheumatoid arthritis, using a 'sawtooth' approach to 
management results in a remission rate of about 30% which is substantially 
higher than traditional pyramid treatment (Fries JF 1990, Mottonen T, 
Paimela L, et al 1996 ). With the 'sawtooth' approach, combinations of anti 
rheumatic drugs are used from initial diagnoses, the patient is reviewed at 
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frequent intervals, and treatment goals are established in terms of a reduction 
on the disease activity. If no appreciable reduction in disease activity is 
noted, corticosteroids or other anti rheumatic drugs are added. 
A. Non steroidal Anti-inflammatory Drugs (NSAIDs) 
NSAIDs has the capacity to block the activity of cyclo-oxygenase enzyme 
and therefore the production of prostaglandin, prostacyclin and 
thromboxanes. This is important to exert action as an analgesic, anti-
inflammatory and antipyretic properties. However the used of NSAIDs has 
fallen worldwide due to their toxic side effects particularly gastric irritation 
(Peter Brooks 1998). 
It is now understood that the cyclo-oxygenase enzyme system that produces 
prostaglandin consists of at least 2 basic isofonns, the cyclo-oxygenase 1 
and cyclo-oxygenase 2 (Bahkle YS et al 1996). 
The cyclo-oxygenase 1 performs 'housekeeping' duties, maintaining a 
normal gastrointestinal mucosa and renal blood flow while cyclo-oxygenase 
2 is the inducible form seen in inflammation site, the brain and the colon 
cancer cells. 
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Newer drugs is the specific cyclo-oxygenase 2(COX-2) inhibitors such as 
rofecoxib and celecoxib (Emery P, et al 2001). The rationale for the 
development of these newer drugs is to prevent inhibition of all type of 
prostaglandin particularly in the gastric mucosa which acts as gastric mucosa 
protective effects. The effectiveness and low incidence of gastrointestinal or 
renal side effects of such drugs as meloxicam have been shown in clinical 
trials (Mueller C et al1996, Ford Hutchinson A 1997). 
B. Glucocorticoid 
Mechanism of glucocorticoid action in affective symptomatic therapy for 
RA are still poorly understood, and there has been only limited success in 
the search for effective but less toxic steroid preparations (Sam Panthakalam 
2001). Low dose of less than 7.5 mg/daily prednisolone has been advocated 
as useful additive therapy to control symptoms (Fauci et al 1998). 
Meta-analysis of short term low dose prednisolone (<15 mg/daily) versus 
placebo and NSAIDs in rhewnatoid arthritis has shown that prednisolone in 
low doses may be used intermittently in patients with RA, particularly if the 
disease cannot be controlled by other means (Peter C Gotzsche, Helle Krogh 
Johansen 1998). 
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C. Disease Modifying Anti Rheumatic Drugs (DMARDs) 
Long term data support the view that anti rheumatic drugs reduce long term 
disability in rheumatoid arthritis. In a study nearly 3000 patients with 
rheumatoid arthritis followed up for an average of 9 years, consistent use of 
DMARDs (hydroxychloroquine, sulphasalazine, auronofm, intramuscular 
gold, D-penicillamine, methotrexate and azathioprine) were associated with 
better long tenn disability index detennined by the Health Assessment 
Questionnaire, and this effect occurred over all periods of disease duration 
(Fries JF, William CA, et a11996). 
NSAIDs and prednisolone failed to show this reduction in disability. These 
data suggest that consistent use of anti rheumatic drugs may reduce long 
term disability by up to 30%. 
Another study has shown that if patients whose rheumatoid arthritis is well 
controlled by disease modifying agents are given placebo instead of their 
anti rheumatic drugs, flare up of the disease occurs in a considerable number 
(Wolde ST, Breedveld FC, et all996). 
Several other randomized, non-placebo controlled clinical trial in early RA 
have compared the effects of various therapeutic combinations with 
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conventional monotherapeutic strategies. These combined therapeutic 
regimens have generally included methotrexate (MTX), sulphasalazine, and 
hydroxychloroquine . Combination of MTX and sulphasalazine have been 
shown to be better than MTX alone (Haagsma CJ et al 1994, Boers M et al 
1997, Dougados Met al1999). 
Cyclosporin A provides additional benefit in patients who do not respond 
adequately to MTX {Tugwell P, Pincus T, et al 1995), and weekly MTX, 
sulphasalazine, and hydroxychloroquine are better than MTX or MTX plus 
sulphasalazine over a two year period without an increased in toxicity 
(O'Dell JR, Haire CE et al1996). 
fu a recent study, a combination of prednisolone (60 mg daily tapering to 7.5 
mg daily at six weeks intervals), sulphasalazine (2 grams daily), and MTX 
(7.5 mg weekly) was shown to be better than sulphasalazine alone over 56 
weeks in early RA (Boers Met al1997). Use of prednisolone in combination 
is increasing after reports that it reduces erosion rates in RA (Kirwan JR 
1995). 
One of the major limitation of DMARDs is that their association with 
considerable toxicity, and therefore careful patient monitoring is necessary. 
Another problem with DMARDs is that discontinuing treatment is patients 
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who are in remission can lead to recurrence of synovitis (i.e., a flare). This 
observation was supported by a randomized, double blind, placebo 
controlled, multicenter study, which evaluated the effect of terminating 
second line therapy in 285 patients with a favorable response to treatment 
(ten Wolde S, Breedveld FC, et al1996). 
D. Immunosuppressive Agent 
The immunosuppressive drugs azathioprine and cyclophosphamide have 
been shown to be effective and exert therapeutic effects similar to those of 
the DMARDs. These agents cause variety of side effects and therefore these 
drugs have been reserved for patients who have clearly failed therapy with 
DMARDs ( Fauci et al 1998). 
E. Tumor Necrosis Factor- targeted therapy (Infliximab and Etanercept) 
Since TNF plays a pivotal role in the host's immune system, a new era in the 
treatment of RA focused on 2 different approaches to decreases the activity 
of tumor necrosis factor (TNF). The acton of TNF are mediated by its 
binding to 2 different receptors (p55 and p75) on a group of cells that 
includes neutrophils, vascular endothelial cells, and fibroblast. These 
receptor are also found in soluable form in the serum and synovial fluid and 
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may act to regulate TNF (O'Dell R 1999). Two different approaches are 
available to decrease TNF activity: treatment with anti-TNF-alpha 
antibodies (lnfliximab) and administration of soluable TNF receptors 
(Etanercept). Both of these approaches have produced substantial 
improvement in patients with RA (Kavanaugh AF 1998). 
W einblatt and collegues report significant improvement when etanercept 
was added to therapy with MTX for patients with RA. Seventy one percent 
of the patients given etanercept plus MTX had a twenty percent 
improvement in measures of disease activity as compared to twenty seven 
percent in placebo group (Weinblatt MEet all999).The place of these new 
TNF-blocking agents has yet to be clarified due to long term consequences 
and effectiveness of these agents are not yet fully understood. 
F. Stem Cell Transplantation 
Stem cell transplantation might offer the ability to give much higher doses of 
chemotherapy with the change of possibly ablating the autoimmune disease 
completely. However, as mortality from autologous stem cell rescue is 
around 1 %, this treatment can now be considered for patients with severe 
progressive connective tissue disease (Peter Brooks 1998). 
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1.3.5. Respiratory Involvement In Rheumatoid Arthritis 
Rheumatoid arthritis is a disease that primarily affects the joint, but it also 
involves other organs and tissues, including the lungs and pleura. 
Pleuropulmonary disease is more common in patient with RA who have 
severe chronic articular disease, high titers of rheumatoid factor, 
subcutaneous nodules, and other systemic manifestation such as cutaneous 
vasculitis. 
The pleuropulmonary manifestation include pleurisy, pulmonary nodules, 
ILD, bronchiolitis obliterans and pulmonary hypertension. Pleural 
involvement by the rheumatoid process is the most common thoracic 
complication of RA and accounts for attack of pleurisy with and without 
effusion. Interstitial pneumonitis and pleural disease may precede articular 
manifestations (Swhwarz MI, 1993). 
The intrapulmonary rheumatoid or necrobiotic nodule, which is 
pathologically identical to subcutaneous nodule in rheumatoid arthritis, is 
more common in men than in women. The lung nodules may wax and wane 
with the appearance of subcutaneous nodules and the activity ofRA. In other 
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instances, they may completely dissapear or may continue to increase in size 
and numbers for years (Gary W.H., 1979). 
Although many of the patients with RA and ILD may be asymptomatic, they 
typically present with dyspneoa and a non productive cough. Other 
symptoms such as fever, pleuritic chest pain, and haemoptysis are distinctly 
less common, unless there are co-existing rheumatoid nodule or pleural 
disease. Clubbing may be present in fifty to seventy five percent of these 
patients, and crepitations are usually audible especially over the lower lung 
fields (Gary W.H., 1979). 
Chronic airway obstruction is a common finding in RA. In a study by 
Geddes et al of 1 00 patients with RA and normal chest radiographs and 84 
control subjects matched for age, sex, and smoking habits, indices of air 
flow obstruction (FEV1, FEV11FVC) were significantly lower in patients 
with RA (Geddes et al, 1979). In a more recent study of another series of 
100 patients with RA, the prevalence of airway obstruction (FEV1, 
FEV/FVC, FEF Z5-15 or FEF 25-75/FVC) in 81 non-smoking patients was 
16% (Vergnenegre A. et al, 1997). This was significantly higher than a 
comparison groups of patients with non-RA joint disease matched for age 
and sex. 
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